You are here

Home » Content

Kawasaki Hastalığında Güncel Gelişmeler

Recent Advances in Kawasaki Disease

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2017
DOI: 
10.5505/abantmedj.2017.49379

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Kawasaki disease is an acute febrile disease inchildren formerly known as mucocutaneous lymphnode disease or infantile polyarteritis nodosa. The disease, a systemic vasculitis of unknown etiology, in which the medium-sized blood vessels are affected, is frequently seen in children under five years of age. Organ systems, mainly the blood vessels, skin, mucous membranes, and lymph nodes are involved. The rarest but the most serious effect of the disease is on the heart, where it can cause fatal coronary artery aneurysms in untreated children. Therefore, early diagnosis, timely and appropriate treatment approach is very important. In this review, diagnosis, treatment processes and prognostic features of Kawasaki disease, also an important cause of morbidity in our country, were discussed.
Bookmark/Search this post with
Abstract (Original Language): 
Kawasaki hastalığı, daha önceleri mukokütanöz lenf nodu hastalığı veya infantil poliarteritis nodoza olarak da bilinen çocuklarda görülen akut febril bir hastalıktır. Hastalık, nedeni tam olarak bilinmeyen sistemik bir vaskülit olarak orta çaplı damar tutulumu ile seyreder ve çoğunlukla 5 yaş altı çocuklarda görülür. Kan damarları, cilt, muköz membranlar ve lenf nodları başta olmak üzere birçok organ sistemi etkilenir. En Nadir fakat en önemli etkilerinden biri kalp üzerinedir, tedavi edilmeyen çocuklarda fatal koroner arter anevrizmalarına neden olabilmektedir. Bu nedenle tanının erken konması, tedavinin zamanında ve uygun bir şekilde planlanması oldukça önemlidir. Bu derlemede ülkemizde de önemli bir morbidite nedeni olan Kawasaki hastalığının tanı, tedavi süreçleri ve prognostik özellikleri tartışılmıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-kawasaki-hastaliginda-guncel-gelismeler.pdf
  • 2
77
85
  • Turkish

REFERENCES

References: 

1. Kawasaki T. Acute febrile mucocutaneous syndrome with
lymphoid involvement with specific desquamation of the
fingers and toes in children. Arerugi, 1967; 16:178-222.
2. Scuccimarri R. Kawasaki disease. Pediatr Clin North Am,
2012; 59:425-45.
3. Lin YT, Manlhiot C, Ching JC, Han RK, Nield LE, Dillenburg
R, Pepelassis D, Lai LS, Smythe JF, Chahal N, Yeung RS,
McCrindle BW. Repeated systematic surveillance of
Kawasaki disease in Ontario from 1995 to 2006. Pediatr Int,
2010; 52:699-706.
4. Ozen S, Bakkaloglu A, Dusunsel R, Soylemezoglu O, Ozaltin
F, Poyrazoglu H, Kasapcopur O, Ozkaya O, Yalcinkaya F,
Balat A, Kural N, Donmez O, Alpay H, Anarat A, Mir S, Gur-
Guven A, Sonmez F, Gok F. Childhood vasculitides in
Turkey: a nationwide survey. Clin Rheumatol, 2007;
26:196-200.
5. Gulhan B, Kesici S, Beken S, Cilsal E, Kale G, Alehan D, Kara
A, Ozen S. Varying clinical features of Turkish Kawasaki
disease patients. Turk J Pediatr, 2012; 54:1-6.
6. Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama
Y, Kojo T, Uehara R, Kotani K, Yanagawa H. Descriptive
epidemiology of Kawasaki disease in Japan, 2011-2012:
from the results of the 22nd nationwide survey. J
Epidemiol, 2015; 25:239-45.
7. Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai
M, Yanagawa H, Kawasaki T. Kawasaki disease in families.
Pediatrics, 1989; 84:666-9.
8. De Ferranti SD, Newburger JW. Kawasaki disease
(Mucocutaneous lymph node syndrome). In: Allen HD,
Driscoll DJ, Shaddy RE, Feltes TF (eds). Moss and Adams
heart disease in infants, children, and adolescents:
including the fetus and young adult (8th ed). Philadelphia:
Wolters Kluwer Health/Lippincott Williams & Wilkins,
2013.
9. Son MBF, Newburger JW. Kawasaki disease. In: Kliegman
R, Stanton BF, St Geme JW, Schor NF (eds). Nelson
textbook of pediatrics (20th ed). Philadelphia: Saunders,
2016.
10. Barron K, DeCunto C, Montalvo J, Orson F, Lewis D.
Abnormalities of immunoregulation in Kawasaki
syndrome. J Rheumatol, 1988; 15:1243-9.
11. Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW,
Yashiro M, Nakamura Y, Yanagawa H, Wakui K, Fukushima
Y, Kishi F, Hamamoto K, Terai M, Sato Y, Ouchi K, Saji T,
Nariai A, Kaburagi Y, Yoshikawa T, Suzuki K, Tanaka T, Nagai
T, Cho H, Fujino A, Sekine A, Nakamichi R, Tsunoda T,
Kawasaki T, Hata A. ITPKC functional polymorphism
associated with Kawasaki disease susceptibility and
formation of coronary artery aneurysms. Nat Genet, 2008;
40:35-42.
12. Fujiwara H, Hamashima Y. Pathology of the heart in
Kawasaki disease. Pediatrics, 1978; 61:100-7.
13. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani
LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore
RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ,
Falace DA, Taubert KA. Diagnosis, treatment, and longterm
management of Kawasaki disease: a statement for
health professionals from the Committee on Rheumatic
Fever, Endocarditis and Kawasaki Disease, Council on
Cardiovascular Disease in the Young, American Heart
Association. Circulation, 2004; 110:2747-71.
14. Printz BF, Sleeper LA, Newburger JW, Minich LL, Bradley T,
Aykan HH ve Özkutlu S
Abant Med J 2017;6(2):79-87 85
Cohen MS, Frank D, Li JS, Margossian R, Shirali G,
Takahashi M, Colan SD. Noncoronary cardiac
abnormalities are associated with coronary artery dilation
and with laboratory inflammatory markers in acute
Kawasaki disease. J Am Coll Cardiol, 2011; 57:86-92.
15. Tatara K, Kusakawa S. Long-term prognosis of giant
coronary aneurysm in Kawasaki disease: an angiographic
study. J Pediatr, 1987; 111:705-10.
16. Harada K. Intravenous gamma-globulin treatment in
Kawasaki disease. Acta Paediatr Jpn, 1991; 33:805-10.
17. Baer AZ, Rubin LG, Shapiro CA, Sood SK, Rajan S, Shapir Y,
Romano A, Bierman FZ. Prevalence of coronary artery
lesions on the initial echocardiogram in Kawasaki
syndrome. Arch Pediatr Adolesc Med, 2006; 160:686-90.
18. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian
J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, et al.
A single intravenous infusion of gamma globulin as
compared with four infusions in the treatment of acute
Kawasaki syndrome. N Engl J Med, 1991; 324:1633-9.
19. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment
of immune globulin-resistant Kawasaki disease with pulsed
doses of corticosteroids. J Pediatr, 1996; 128:146-9.
20. Terai M, Shulman ST. Prevalence of coronary artery
abnormalities in Kawasaki disease is highly dependent on
gamma globulin dose but independent of salicylate dose. J
Pediatr, 1997; 131:888-93.
21. Ishii M, Ueno T, Akagi T, Baba K, Harada K, Hamaoka K,
Kato H, Tsuda E, Uemura S, Saji T, Ogawa S, Echigo S,
Yamaguchi T. Guidelines for catheter intervention in
coronary artery lesion in Kawasaki disease. Pediatr Int,
2001; 43:558-62.
22. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y,
Kazue T, Eto G, Yamakawa R. Long-term consequences of
Kawasaki disease. A 10- to 21-year follow-up study of 594
patients. Circulation, 1996; 94:1379-85.

Thank you for copying data from http://www.arastirmax.com